Quince Therapeutics, Inc. Expense Breakdown
No Expense Breakdown for QNCX on this site yet.
- 2026-06-30: Reportable $79.78M.
- 2025-06-30: Reportable $10.43M.
Source checked: the stored Expense Breakdown page for QNCX.
Expenses by product
Operating expenses: each quarter (3 month)
| Quarter end | Reportable |
|---|---|
| 2026-06-30 | $79.78M |
| 2025-06-30 | $10.43M |
Other General And Administrative Expense: each quarter (3 month)
| Quarter end | Reportable |
|---|---|
| 2026-06-30 | $632.00K |
| 2025-06-30 | $684.00K |
Share-based Payment Arrangement, Expense: each quarter (3 month)
| Quarter end | Reportable |
|---|---|
| 2026-06-30 | $8.91M |
| 2025-06-30 | $834.00K |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |